trending Market Intelligence /marketintelligence/en/news-insights/trending/imSOn-fASg0r89rRXEEfXQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Y-mAbs' experimental cancer vaccine wins US FDA's rare pediatric disease tag

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Y-mAbs' experimental cancer vaccine wins US FDA's rare pediatric disease tag

Y-mAbs Therapeutics Inc. said the U.S. Food and Drug Administration granted rare pediatric disease designation for its experimental cancer treatment GD2-GD3 Vaccine.

The New York-based biotech is developing GD2-GD3 Vaccine for treating children with neuroblastoma, a kind of cancer that forms from immature nerve cells and usually begins in the adrenal glands. It typically impacts children younger than five.

GD2-GD3 Vaccine was originally developed by Memorial Sloan Kettering Cancer Center, a private company that engages in cancer prevention, treatment and research activities. The research center licensed the therapy to San Diego-based biotech MabVax Therapeutics Holdings Inc.

Y-mAbs licensed the drug from MabVax for treating neuroblastoma in 2018 and has the rights to commercialize the drug.

The FDA grants priority review vouchers to eligible companies following approval of treatments with a rare pediatric disease designation. The voucher can be redeemed to get an accelerated six-month review instead of 10 months for a future marketing application with the FDA. Y-mAbs will pay MabVax 20% of net income from the potential sale of a voucher, if granted.

Y-mAbs is evaluating the drug for safety and effectiveness in patients with neuroblastoma in a Phase 1/2 trial. The patients received seven injections within a year to prevent relapse. The company plans to start another midstage study of GD2-GD3 Vaccine in the same indication in 2020.

Earlier in December, Y-mAbs started a rolling submission of a biologics license application with the FDA for another therapy for neuroblastoma, called naxitamab, which treats cancer that has returned or has not responded to earlier treatment.